BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 19433314)

  • 41. Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
    Kim MH; Cho HS; Jung M; Hong MH; Lee SK; Shin BA; Ahn BW; Jung YD
    Int J Oncol; 2005 Jun; 26(6):1669-74. PubMed ID: 15870884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
    Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
    Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physical association of uPAR with the alphaV integrin on the surface of human NK cells.
    Gellert GC; Goldfarb RH; Kitson RP
    Biochem Biophys Res Commun; 2004 Mar; 315(4):1025-32. PubMed ID: 14985115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
    Saldanha RG; Molloy MP; Bdeir K; Cines DB; Song X; Uitto PM; Weinreb PH; Violette SM; Baker MS
    J Proteome Res; 2007 Mar; 6(3):1016-28. PubMed ID: 17330942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
    Albo D; Berger DH; Tuszynski GP
    J Surg Res; 1998 Apr; 76(1):86-90. PubMed ID: 9695745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
    Tan X; Egami H; Nozawa F; Abe M; Baba H
    Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.
    Binder BR; Mihaly J; Prager GW
    Thromb Haemost; 2007 Mar; 97(3):336-42. PubMed ID: 17334498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth.
    Aguirre-Ghiso JA; Ossowski L; Rosenbaum SK
    Cancer Res; 2004 Oct; 64(20):7336-45. PubMed ID: 15492254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
    Ma Z; Webb DJ; Jo M; Gonias SL
    J Cell Sci; 2001 Sep; 114(Pt 18):3387-96. PubMed ID: 11591826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y; Hayashi Y; Imai Y; Itoh H
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
    Shiratsuchi T; Ishibashi H; Shirasuna K
    J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
    Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
    Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
    Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
    J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin inhibits highly invasive prostate cancer cells.
    Lloyd FP; Slivova V; Valachovicova T; Sliva D
    Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Hashiba Y; Kawashiri S; Tanaka A; Nakagawa K; Matsuoka Y; Kogo M; Yamamoto E
    Oral Oncol; 2005 Nov; 41(10):971-7. PubMed ID: 16129656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.